Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

Bibliographic Details
Main Authors:	Wong, Deborah JL, Robert, Lidia, Atefi, Mohammad S, Lassen, Amanda, Avarappatt, Geetha, Cerniglia, Michael, Avramis, Earl, Tsoi, Jennifer, Foulad, David, Graeber, Thomas G, Comin-Anduix, Begonya, Samatar, Ahmed, Lo, Roger S, Ribas, Antoni
Format:	Online
Language:	English
Published:	BioMed Central 2015
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4488977/

Similar Items

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
by: Wong, Deborah JL, et al.
Published: (2014)

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma
by: Atefi, Mohammad, et al.
Published: (2015)

Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma
by: Lassen, Amanda, et al.
Published: (2014)

Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma
by: Homet Moreno, Blanca, et al.
Published: (2015)

NRAS mutant melanoma – undrugable?
by: Posch, Christian, et al.
Published: (2013)

MEK inhibitors for the treatment of NRAS mutant melanoma
by: Sarkisian S, et al.
Published: (2018-08-01)

Playing POLO-like kinase in NRAS mutant melanoma
by: Chen, Hsin-Yi, et al.
Published: (2015)

BRAF-mutant hematopoietic malignancies
by: Abdel-Wahab, Omar, et al.
Published: (2014)

CRAF R391W is a melanoma driver oncogene
by: Atefi, Mohammad, et al.
Published: (2016)

Targeting mutant BRAF in colorectal cancer
by: Carroll, David, et al.
Published: (2013)

Optimizing the treatment of BRAF mutant melanoma
by: Settleman, Jeff
Published: (2014)

Dabrafenib for treatment of BRAF-mutant melanoma
by: Kainthla, Radhika, et al.
Published: (2013)

Variation of mutant allele frequency in NRAS Q61 mutated melanomas
by: Zofia Hélias-Rodzewicz, et al.
Published: (2017-07-01)

Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma
by: Kiessling, Michael K., et al.
Published: (2016)

BET and BRAF inhibitors act synergistically against BRAF‐mutant melanoma
by: Paoluzzi, Luca, et al.
Published: (2016)

Endosomal acidification inhibitors for the treatment of BRAF mutant tumors
by: Espinosa, Lluís
Published: (2015)

Variations of BRAF mutant allele percentage in melanomas
by: Hélias-Rodzewicz, Zofia, et al.
Published: (2015)

Novel combination therapies for BRAF-mutant melanoma
by: McArthur, Grant A
Published: (2015)

Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway
by: Atefi, Mohammad, et al.
Published: (2011)

NRAS and BRAF Mutations in Melanoma-Associated Nevi and Uninvolved Nevi
by: Tschandl, Philipp, et al.
Published: (2013)

Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma
by: Colombino, Maria, et al.
Published: (2013)

BRAF and NRAS Mutations are Heterogeneous and Not Mutually Exclusive in Nodular Melanoma
by: Chiappetta, Caterina, et al.
Published: (2015)

BRAF/NRAS wild-type melanoma, NF1 status and sensitivity to trametinib
by: Ranzani, Marco, et al.
Published: (2015)

BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells
by: Goulielmaki, Maria, et al.
Published: (2016)

The longevity of tor1Δ, sch9Δ, and ras2Δ mutants depends on actin dynamics in Saccharomyces cerevisiae
by: Liu, Ying, et al.
Published: (2015)

Deregulated Nras Expression in Knock-In Animals Harboring a Gammaretroviral Long Terminal Repeat at the Nras/Csde1 Locus
by: Ballarín-González, Borja, et al.
Published: (2013)

Chromosomal Instability in BRAF Mutant, Microsatellite Stable Colorectal Cancers
by: Bond, Catherine E., et al.
Published: (2012)

The RhoJ-BAD signaling network: An Achilles' heel for BRAF mutant melanomas.
by: Rolando Ruiz, et al.
Published: (2017-07-01)

Mutant BRAF in low-grade epilepsy-associated tumors and focal cortical dysplasia
by: Marucci, Gianluca, et al.
Published: (2014)

ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma
by: Smit, Marjon A, et al.
Published: (2014)

BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies
by: Spagnolo, Francesco, et al.
Published: (2015)

Inhibition of Cell Proliferation in an NRAS Mutant Melanoma Cell Line by Combining Sorafenib and α-Mangostin
by: Xia, Yun, et al.
Published: (2016)

Combined inhibition of MEK and Plk1 has synergistic anti-tumor activity in NRAS mutant melanoma
by: Posch, C, et al.
Published: (2015)

MIG6 is MEK-regulated and affects EGF-induced migration in mutant NRAS melanoma
by: Vu, Ha Linh, et al.
Published: (2015)

Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer
by: Vujic, Igor, et al.
Published: (2014)

α-Mangostin, a Natural Agent, Enhances the Response of NRAS Mutant Melanoma to Retinoic Acid
by: Xia, Yun, et al.
Published: (2016)

Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers
by: Corcoran, Ryan B., et al.
Published: (2011)

Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy
by: Robinson, Giles W, et al.
Published: (2014)

Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth
by: Sweetlove, Melanie, et al.
Published: (2015)

Intermittent BRAF Inhibition Can Achieve Prolonged Disease Control in BRAF Mutant Melanoma
by: Jain, Tania, et al.
Published: (2015)